Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain-Reference-Cited by-同舟云学术

Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain

Published:2021-09 Issue:26 Volume:17 Page:3465-3476
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Hernández-Rivas José-Ángel¹,Arnao Mario²,Arguiñano Pérez José Maria³,Rubio Araceli⁴,García Esther Gónzalez⁵,de Miguel Dunia⁶,Cherepanov Dasha⁷,Romanus Dorothy⁷,Verleger Katharina⁸,Johnson Courtney⁹,Corman Shelby L⁹^ORCID,Grande Marta¹⁰¹¹,Persona Ernesto Pérez¹²

Affiliation:

1. Department of Hematology, Universidad Complutense, Madrid 28040, Spain

2. Department of Hematology, Hospital La Fe, Valencia 46026, Spain

3. Department of Hematology, Complejo Hospitalario De Navarra, Navarra 31008, Spain

4. Department of Hematology, Hospital Miguel Servet, Zaragoza, 50009, Spain

5. Department of Hematology, Hospital De Cabueñes, Gijón, Asturias 33394 Spain

6. Department of Hematology, Hospital Universitario de Guadalajara, Guadalajara 19002, Spain

7. Takeda Pharmaceutical Company Limited, Cambridge, MA 02139, USA

8. OPEN Health, Berlin 10177, Germany

9. OPEN Health, Bethesda, MD 20814, USA

10. Takeda Farmaceutica España, Madrid 28046, Spain

11. Universidad de Alcalá, Alcalá de Henares, Madrid 28801, Spain

12. Department of Hematology, HospitalUniversitario de Alava, Álava 01001, Spain

Abstract

Aim: To describe treatment patterns and outcomes in nontransplant newly diagnosed multiple myeloma (NDMM) patients in Spain. Methods: This retrospective study included two cohorts of NDMM patients diagnosed between 1 January 2012 to 31 December 2013 and 1 April 2016 to 31 March 2017. Results: Among 113 patients, proteasome inhibitor (PI) + alkylator combinations (49%) and PI-based regimens without an alkylator (30%) were the most common first-line (1L) therapies. Use of PI + immunomodulatory drug-based regimens increased between the cohorts; PI-based regimens without an alkylator/immunomodulatory drug decreased. Use of 1L oral regimens was low but increased over time; use of maintenance therapy was low across both periods. Median 1L duration of treatment was 6.9 months. Conclusion: Short 1L duration of treatment and low use of 1L oral regimens and maintenance therapy highlight unmet needs in NDMM.

Funder

Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-0301

Reference33 articles.

1. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe

2. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

3. Modern treatments and future directions for newly diagnosed multiple myeloma patients

4. The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

5. Frontline therapy for newly diagnosed patients with multiple myeloma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients;Targeted Oncology;2023-09